BASF, Shares

BASF Shares Sit Between Two Warring Price Targets After Evonik Deal Collapses

Published on 11/19/2026 at 19:41 | Editorial boerse-global.de
BASF shares sit between Jefferies' 44-euro and Bernstein's 59-euro targets after the failed Evonik takeover, as analysts weigh synergy doubts against a possible revival.
BASF, Shares, Sit, Between, Two, Warring, Price, Targets, After, Evonik Illustration mit AI erstellt.

BASF's stock is trading squarely between two sharply divergent broker targets, and the gap says as much about the failed Evonik takeover as it does about the chemicals giant itself. Jefferies has reiterated its 44-euro target, implying further downside, while Bernstein is holding at 59 euros — a spread that leaves the current 50.73-euro price almost exactly in the middle.

The two houses agree on the facts of the abandoned deal but read them in opposite directions. BASF walked away from its pursuit of Evonik after the Essen-based specialty chemicals group rejected two non-binding all-cash offers, the last pitched at 24 euros per Evonik share. BASF had signalled a further moderate increase was possible but concluded that Evonik's standalone business outlook — and the risks attached to it — did not justify paying more.

Synergy Doubts at Jefferies

For Jefferies analyst Priyanka Patel, the retreat validates her cautious stance. A combination would have carried strategic merit, she concedes, but BASF's heavy exposure to Europe and the danger of failing to deliver the promised synergies made the acquisition less appealing for the group. She keeps her underperform-equivalent view and the 44-euro target unchanged.

Management framed the decision as a matter of capital discipline, pointing to its attractive distribution policy. No additional payout was announced alongside the withdrawal.

Should investors sell immediately? Or is it worth buying BASF?

Bernstein's James Hooper takes the other side of the argument, holding his 59-euro target. He does not rule out that Evonik's steep share-price slide following the rejection could shift the mood among its shareholders, who might press the supervisory board to reopen talks with BASF. That remains a scenario rather than a resumption of negotiations. The RAG-Stiftung, Evonik's anchor shareholder, did not back the transaction, according to the Frankfurter Allgemeine Zeitung.

Evonik interim chief Claus Rettig, meanwhile, has doubled down on independence, saying the company intends to lift its value under its own steam and to play an active role in industry consolidation itself.

Political Headwinds and a Mixed Trading Week

The collapse followed mounting opposition. Hendrik Wüst, premier of North Rhine-Westphalia, came out against the takeover yesterday. Reuters, citing people close to Evonik, reported that the group could have turned down even a higher BASF offer absent a convincing industrial rationale for the combination.

Price action has been choppy. The stock slipped yesterday as resistance to the deal hardened, then recovered 0.4% to 51.49 euros today.

Away from the M&A drama, BASF has been busy on the portfolio front. On 12 November it agreed to sell its global mining solutions business to SNF, a deal covering the Cork production site and roughly 140 employees. Completion is targeted for 2027, subject to regulatory clearance and customary closing conditions.

BASF at a turning point? This analysis reveals what investors need to know now.

In its agricultural unit, BASF said on Monday it will market its Nemasphere technology worldwide, putting the peak sales potential at more than 300 million euros. Soybean varieties carrying the technology are due to launch in the US and Brazil from 2028. The group also struck a cooperation with DWE yesterday to speed up the delivery of modular plants for sustainable methanol production, combining DWE's power-to-liquid technology with BASF's SYNSPIRE catalysts.

For investors, the immediate question is less about Evonik than about how much weight to give each side of the risk ledger. Jefferies conditions any deal benefit on synergies that can actually be realised; Bernstein keeps the door ajar but ties any revival to how Evonik's shareholders behave.

Ad

BASF Stock: New Analysis - 19 November

Fresh BASF information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated BASF analysis...

Disclaimer...
en | DE000BASF111 | BASF | boerse | 70537845 |